Literature DB >> 28681469

Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome.

Jan Valka1, Jitka Vesela1, Hana Votavova1, Michaela Dostalova-Merkerova1, Zuzana Horakova1, Vit Campr2, Jana Brezinova1, Zuzana Zemanova3, Anna Jonasova4, Jaroslav Cermak1, Monika Belickova1.   

Abstract

BACKGROUND: The high incidence of mutations and cytogenetic abnormalities in patients with myelodysplastic syndrome (MDS) suggests that defects in DNA repair mechanisms. We monitored DNA repair pathways in MDS and their alterations during disease progression.
METHODS: Expression profiling of DNA repair genes was performed on CD34+ cells, and paired samples were used for monitoring of RAD51 and XRCC2 gene expression during disease progression. Immunohistochemical staining for RAD51 was done on histology samples.
RESULTS: RAD51 and XRCC2 showed differential expression between low-risk and high-risk MDS (P<.0001), whereas RPA3 was generally decreased among the entire cohort (FC=-2.65, P<.0001). We demonstrated that RAD51 and XRCC2 expression gradually decreased during the progression of MDS. Down-regulation of XRCC2 and RAD51 expression was connected with abnormalities on chromosome 7 (P=.0858, P=.0457). Immunohistochemical staining revealed the presence of RAD51 only in the cytoplasm in low-risk MDS, while in both the cytoplasm and nucleus in high-risk MDS. The multivariate analysis identified RAD51 expression level (HR 0.49; P=.01) as significant prognostic factor for overall survival of patients with MDS.
CONCLUSIONS: Our study demonstrates that the expression of DNA repair factors, primarily RAD51 and XRCC2, is deregulated in patients with MDS and presents a specific pattern with respect to prognostic categories.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990RAD51zzm321990; DNA repair; homologous recombination; myelodysplastic syndrome

Mesh:

Substances:

Year:  2017        PMID: 28681469     DOI: 10.1111/ejh.12920

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes.

Authors:  Michaela Dostalova Merkerova; Jiri Klema; David Kundrat; Katarina Szikszai; Zdenek Krejcik; Andrea Hrustincova; Iva Trsova; Anh Vu LE; Jaroslav Cermak; Anna Jonasova; Monika Belickova
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

Review 2.  Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

Authors:  Alex Aleshin; Peter L Greenberg
Journal:  Blood Adv       Date:  2018-10-23

3.  Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?

Authors:  Howard Lopes Ribeiro Junior; Roberta Taiane Germano de Oliveira; Daniela de Paula Borges; Marília Braga Costa; Izabelle Rocha Farias; Antônio Wesley Araújo Dos Santos; Silvia Maria Meira Magalhães; Ronald Feitosa Pinheiro
Journal:  Med Oncol       Date:  2019-10-30       Impact factor: 3.064

4.  RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.

Authors:  Monika Kaisrlikova; Jitka Vesela; David Kundrat; Hana Votavova; Michaela Dostalova Merkerova; Zdenek Krejcik; Vladimir Divoky; Marek Jedlicka; Jan Fric; Jiri Klema; Dana Mikulenkova; Marketa Stastna Markova; Marie Lauermannova; Jolana Mertova; Jacqueline Soukupova Maaloufova; Anna Jonasova; Jaroslav Cermak; Monika Belickova
Journal:  Leukemia       Date:  2022-05-03       Impact factor: 12.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.